FDA Says, 'Wait' To Dying Men; Coast-To-Coast Prostate Cancer Demonstrations on May 30th in Protest of FDA Failure to Approve Safe, Effective Imm...( DUBLIN Ohio May 12 /- On May 30 2...),Health

DUBLIN, Ohio, May 12 /PRNewswire/ -- On May 30, 2008, CareToLive will take to the streets with coast-to-coast protests in Chicago, New York, Philadelphia, Cleveland, Madison, Atlanta, Seattle, Dearborn, and Tampa. Joining us will be the Cancer Cure Coalition, the Abigail Alliance, A Right To Live, and the Sarcoma Foundation of America. We are asking all patient advocates to come out and attend a protest.

1 in 6 men get prostate cancer. 75 American men die from it every day. The FDA has not approved a treatment for stage IV prostate cancer in over 43 years.

CareToLive, a not for profit corporation, seeks transparency and accountability from the FDA, as to why they disregarded the advice of their hand selected Congressionally mandated Advisory Panel of experts, who voted Provenge overwhelmingly safe and effective. Without cause or explanation, in an unprecedented action, the FDA denied licensure. We are seeking immediate access to Provenge for all men with end stage prostate cancer.

Over a year has passed, and 27,000 American men have died without hope, since the FDA denied the licensure of Provenge, an immunotherapy the FDA panel voted 17-0 safe and overwhelmingly voted effective. This is a noninvasive, non-toxic, immune building treatment, which works by employing your own body's healthy cells to fight the cancer.

Men like Eduardo Garcia, who have had the 3 treatments, have gone from being incapacitated, to living healthy, productive lives, for as long as seven years and counting. Dendreon, the company that perfected this treatment, also has similar treatments for breast, ovarian, colon, lung, kidney, and cervical cancers, in their sights.

The dysfunctional FDA's reason for delay has never been explained, as it was not science based, since survival and safety have been clearly demonstrated.

CareToLive filed a Citizens Petition for the FDA to reconsider the wrongful denial, (the only recourse the FDA allows), on July 2
'/>"/>